<?xml version='1.0' encoding='utf-8'?>
<document id="30185228"><sentence text="A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer."><entity charOffset="62-72" id="DDI-PubMed.30185228.s1.e0" text="paclitaxel" /><entity charOffset="91-102" id="DDI-PubMed.30185228.s1.e1" text="bevacizumab" /><entity charOffset="106-117" id="DDI-PubMed.30185228.s1.e2" text="trastuzumab" /><entity charOffset="128-137" id="DDI-PubMed.30185228.s1.e3" text="letrozole" /><pair ddi="false" e1="DDI-PubMed.30185228.s1.e0" e2="DDI-PubMed.30185228.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30185228.s1.e0" e2="DDI-PubMed.30185228.s1.e1" /><pair ddi="false" e1="DDI-PubMed.30185228.s1.e0" e2="DDI-PubMed.30185228.s1.e2" /><pair ddi="false" e1="DDI-PubMed.30185228.s1.e0" e2="DDI-PubMed.30185228.s1.e3" /><pair ddi="false" e1="DDI-PubMed.30185228.s1.e1" e2="DDI-PubMed.30185228.s1.e1" /><pair ddi="false" e1="DDI-PubMed.30185228.s1.e1" e2="DDI-PubMed.30185228.s1.e2" /><pair ddi="false" e1="DDI-PubMed.30185228.s1.e1" e2="DDI-PubMed.30185228.s1.e3" /><pair ddi="false" e1="DDI-PubMed.30185228.s1.e2" e2="DDI-PubMed.30185228.s1.e2" /><pair ddi="false" e1="DDI-PubMed.30185228.s1.e2" e2="DDI-PubMed.30185228.s1.e3" /></sentence><sentence text="This phase Ib study (NCT00960960) evaluated pictilisib (GDC-0941; pan-phosphatidylinositol 3-kinase inhibitor) plus paclitaxel, with and without bevacizumab or trastuzumab, or in combination with letrozole, in patients with locally recurrent or metastatic breast cancer"><entity charOffset="116-126" id="DDI-PubMed.30185228.s2.e0" text="paclitaxel" /><entity charOffset="145-156" id="DDI-PubMed.30185228.s2.e1" text="bevacizumab" /><entity charOffset="160-171" id="DDI-PubMed.30185228.s2.e2" text="trastuzumab" /><entity charOffset="196-205" id="DDI-PubMed.30185228.s2.e3" text="letrozole" /><pair ddi="false" e1="DDI-PubMed.30185228.s2.e0" e2="DDI-PubMed.30185228.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30185228.s2.e0" e2="DDI-PubMed.30185228.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30185228.s2.e0" e2="DDI-PubMed.30185228.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30185228.s2.e0" e2="DDI-PubMed.30185228.s2.e3" /><pair ddi="false" e1="DDI-PubMed.30185228.s2.e1" e2="DDI-PubMed.30185228.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30185228.s2.e1" e2="DDI-PubMed.30185228.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30185228.s2.e1" e2="DDI-PubMed.30185228.s2.e3" /><pair ddi="false" e1="DDI-PubMed.30185228.s2.e2" e2="DDI-PubMed.30185228.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30185228.s2.e2" e2="DDI-PubMed.30185228.s2.e3" /></sentence><sentence text="" /><sentence text="This was a three-part multischedule study" /><sentence text=" Patients in parts 1 and 2, which comprised 3 + 3 dose escalation and cohort expansion stages, received pictilisib (60-330 mg) plus paclitaxel (90 mg/m2) with and without bevacizumab (10 mg/kg) or trastuzumab (2-4 mg/kg)"><entity charOffset="104-114" id="DDI-PubMed.30185228.s5.e0" text="pictilisib" /><entity charOffset="132-142" id="DDI-PubMed.30185228.s5.e1" text="paclitaxel" /><entity charOffset="171-182" id="DDI-PubMed.30185228.s5.e2" text="bevacizumab" /><entity charOffset="197-208" id="DDI-PubMed.30185228.s5.e3" text="trastuzumab" /><pair ddi="false" e1="DDI-PubMed.30185228.s5.e0" e2="DDI-PubMed.30185228.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30185228.s5.e0" e2="DDI-PubMed.30185228.s5.e1" /><pair ddi="false" e1="DDI-PubMed.30185228.s5.e0" e2="DDI-PubMed.30185228.s5.e2" /><pair ddi="false" e1="DDI-PubMed.30185228.s5.e0" e2="DDI-PubMed.30185228.s5.e3" /><pair ddi="false" e1="DDI-PubMed.30185228.s5.e1" e2="DDI-PubMed.30185228.s5.e1" /><pair ddi="false" e1="DDI-PubMed.30185228.s5.e1" e2="DDI-PubMed.30185228.s5.e2" /><pair ddi="false" e1="DDI-PubMed.30185228.s5.e1" e2="DDI-PubMed.30185228.s5.e3" /><pair ddi="false" e1="DDI-PubMed.30185228.s5.e2" e2="DDI-PubMed.30185228.s5.e2" /><pair ddi="false" e1="DDI-PubMed.30185228.s5.e2" e2="DDI-PubMed.30185228.s5.e3" /></sentence><sentence text=" In part 3, patients received pictilisib (260 mg) plus letrozole (2"><entity charOffset="55-64" id="DDI-PubMed.30185228.s6.e0" text="letrozole" /></sentence><sentence text="5 mg)" /><sentence text=" Primary objectives were evaluation of safety and tolerability, identification of dose-limiting toxicities (DLTs) and the maximum tolerated dose (MTD) of pictilisib, and recommendation of a phase II dosing regimen" /><sentence text=" Secondary endpoints included pharmacokinetics and preliminary antitumor activity" /><sentence text="" /><sentence text="Sixty-nine patients were enrolled; all experienced at least one adverse event (AE)" /><sentence text=" Grade ≥ 3 AEs, serious AEs, and AEs leading to death were reported in 50 (72" /><sentence text="5%), 21 (30" /><sentence text="4%), and 2 (2" /><sentence text="9%) patients, respectively" /><sentence text=" Six (8" /><sentence text="7%) patients reported a DLT, and the MTD and recommended phase II pictilisib doses were established where possible" /><sentence text=" There was no pictilisib-paclitaxel drug-drug interaction" /><sentence text=" Two (3" /><sentence text="4%) patients experienced complete responses, and 17 (29" /><sentence text="3%) patients had partial responses" /><sentence text="" /><sentence text="Combining pictilisib with paclitaxel, with and without bevacizumab or trastuzumab, or letrozole, had a manageable safety profile in patients with locally recurrent or metastatic breast cancer"><entity charOffset="26-36" id="DDI-PubMed.30185228.s23.e0" text="paclitaxel" /><entity charOffset="55-66" id="DDI-PubMed.30185228.s23.e1" text="bevacizumab" /><entity charOffset="70-81" id="DDI-PubMed.30185228.s23.e2" text="trastuzumab" /><entity charOffset="86-95" id="DDI-PubMed.30185228.s23.e3" text="letrozole" /><pair ddi="false" e1="DDI-PubMed.30185228.s23.e0" e2="DDI-PubMed.30185228.s23.e0" /><pair ddi="false" e1="DDI-PubMed.30185228.s23.e0" e2="DDI-PubMed.30185228.s23.e1" /><pair ddi="false" e1="DDI-PubMed.30185228.s23.e0" e2="DDI-PubMed.30185228.s23.e2" /><pair ddi="false" e1="DDI-PubMed.30185228.s23.e0" e2="DDI-PubMed.30185228.s23.e3" /><pair ddi="false" e1="DDI-PubMed.30185228.s23.e1" e2="DDI-PubMed.30185228.s23.e1" /><pair ddi="false" e1="DDI-PubMed.30185228.s23.e1" e2="DDI-PubMed.30185228.s23.e2" /><pair ddi="false" e1="DDI-PubMed.30185228.s23.e1" e2="DDI-PubMed.30185228.s23.e3" /><pair ddi="false" e1="DDI-PubMed.30185228.s23.e2" e2="DDI-PubMed.30185228.s23.e2" /><pair ddi="false" e1="DDI-PubMed.30185228.s23.e2" e2="DDI-PubMed.30185228.s23.e3" /></sentence><sentence text=" The combination had antitumor activity, and the additive effect of pictilisib supported further investigation in a randomized study" /><sentence text="" /><sentence text="ClinicalTrials" /><sentence text="gov, NCT00960960 " /><sentence text=" Registered on August 13, 2009" /><sentence text="" /></document>